Sign in
Taking peoplePhase 1/2

N-acetylcysteine added to usual care for infected abdominal fluid in liver cirrhosis

Tests adding N-acetylcysteine to treatment of spontaneous bacterial peritonitis in people with liver cirrhosis.

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
25 Oct 2026
Expected to end
1 Jun 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Placebo
  • NAC
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis who have just been diagnosed with spontaneous bacterial peritonitis (SBP), an infection of the fluid in the belly.

Age
18 Years to 65 Years
Sex
All
Disease stage
Liver cirrhosis confirmed by clinical, imaging or tissue findings. Newly diagnosed SBP, with an ascitic fluid PMN white cell count ≥250 cells/mm³ (AASLD criteria). People must have had a needle test of the belly fluid (diagnostic paracentesis).
Earlier treatment
People cannot join if they already had NAC during the current SBP episode.
Biomarker or test result
Ascitic fluid polymorphonuclear (PMN) leukocyte count ≥250 cells/mm³.

Main reasons for not taking part

  • Peritonitis from another cause (secondary bacterial or fungal peritonitis)
  • Recent belly surgery or needing surgery right away
  • Septic shock, kidney failure from liver disease (HRS-AKI) needing rescue therapy, or dialysis at enrolment
  • Pregnancy or breastfeeding
  • Advanced cancer or terminal illness, or allergy to NAC

The registry criteria, word for word

Show all 9 criteriaShow less

Who cannot take part

  • Recent abdominal surgery or requiring immediate surgical intervention
  • Septic shock, established HRS-AKI requiring rescue therapy, or renal replacement therapy at enrollment
  • Previous NAC administration during the current SBP episode
  • Inability to receive oral study medication
  • Known hypersensitivity to NAC
  • Advanced malignancy or terminal illness
  • Secondary bacterial or fungal peritonitis
  • Pregnancy or lactation
  • Participation in another interventional trial that may affect study outcomes

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in Egypt.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Spontaneous bacterial peritonitis (SBP) is one of the most serious infectious complications of liver cirrhosis and ascites. It affects approximately 10-30% of hospitalized patients with decompensated cirrhosis and carries an in-hospital mortality of 20-40% despite appropriate antimicrobial therapy. SBP results from bacterial translocation across the intestinal mucosa together with cirrhosis-associated immune dysfunction, leading to impaired bacterial clearance and exaggerated systemic inflammation. Current international guidelines recommend immediate empirical antibiotic therapy together with intravenous human albumin to reduce the incidence of acute kidney injury (AKI), hepatorenal syndrome, and mortality.

Read full original descriptionShow less

Although this strategy has substantially improved outcomes, treatment failure, persistent infection, renal dysfunction, acute-on-chronic liver failure (ACLF), and early mortality remain common, indicating that currently available therapy does not adequately address all pathogenic mechanisms of SBP. Increasing evidence suggests that oxidative stress is a central contributor to the progression of bacterial infections in cirrhosis. Excessive production of reactive oxygen species aggravates hepatocellular injury, endothelial dysfunction, immune dysregulation, and renal impairment, thereby amplifying systemic inflammatory responses during SBP. Consequently, therapeutic strategies targeting oxidative stress may improve host defense while limiting organ injury.

N-acetylcysteine (NAC) is a precursor of glutathione and one of the most extensively studied antioxidant agents in clinical medicine. Besides restoring intracellular glutathione stores, NAC exerts anti-inflammatory, endothelial-protective, and immunomodulatory effects through inhibition of oxidative stress and pro-inflammatory cytokine production. On the other hand, experimental studies have further demonstrated that NAC can inhibit bacterial biofilm formation, enhance antibiotic penetration, and potentiate antimicrobial activity against several clinically important bacterial pathogens.

Despite these promising biological properties, the therapeutic role of NAC in active SBP has not been established. Previous data have primarily evaluated NAC for hepato- or renal protection in liver disease. While its potential role as an adjunctive antibacterial therapy during active SBP has not been investigated in adequately designed randomized controlled trials. Therefore, the present study will evaluate whether adjunctive NAC improves early treatment response and reduces subsequent organ dysfunction and short-term adverse outcomes.

The 2 groups in the trial

  • CONTROLPlacebo, for comparison

    Treatment: Placebo

  • NACExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjunctive N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis: A Randomized Controlled Trial
Plain-language title
N-acetylcysteine added to usual care for infected abdominal fluid in liver cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07803952, who can take part
Record updated
30 October 2026